1
|
Iqneibi S, Nazzal J, Owda B, Sultan H, Amoudi R, Amarin JZ, Al-Ghnimat S, Ahram M, Al-Hussaini M. Immunohistochemical Expression of p27Kip1, p57Kip2, Cyclin D1, Nestin, and Ki-67 in Ependymoma. Brain Sci 2022; 12:brainsci12020282. [PMID: 35204045 PMCID: PMC8870614 DOI: 10.3390/brainsci12020282] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/30/2021] [Revised: 02/05/2022] [Accepted: 02/08/2022] [Indexed: 11/16/2022] Open
Abstract
p27 and p57 are tumor suppressors that are dysregulated in many cancers. We investigated the immunohistochemical expression of p27 and p57 in ependymoma, with a secondary emphasis on cyclin D1, nestin, and Ki-67. Sixty-five patients diagnosed with ependymoma were included. Clinical and tumoral data were retrieved, and the expression of p27, p57, cyclin D1, nestin, and Ki-67 was measured. Pearson’s χ2 test was used to measure associations and the Kaplan–Meier method was used for survival analysis. p27 underexpression was significantly associated with pseudopalisading necrosis in tumors with foci of necrosis (p = 0.004). Cyclin D1 overexpression was associated with intracranial (p = 0.044), recurrent (p = 0.022) and grade 3 tumors (p = 0.016); nestin overexpression was associated with supratentorial (p = 0.025), mitotically active (p < 0.001), and grade 3 tumors (p = 0.004); Ki-67 overexpression was associated with supratentorial (p = 0.044) and grade 3 tumors (p < 0.001) and the 3 main features of anaplasia. None of the markers were intercorrelated or predictive of overall survival. In conclusion, p27 underexpression in tumors with foci of necrosis signals a pseudopalisading pattern. Cyclin D1, nestin, and Ki-67 are useful markers in ependymoma, but evidence-based cutoff values are required to standardize this interpretation.
Collapse
Affiliation(s)
- Shahad Iqneibi
- School of Medicine, The University of Jordan, Amman 11942, Jordan; (S.I.); (J.N.); (B.O.); (H.S.); (R.A.)
| | - Jamil Nazzal
- School of Medicine, The University of Jordan, Amman 11942, Jordan; (S.I.); (J.N.); (B.O.); (H.S.); (R.A.)
| | - Basma Owda
- School of Medicine, The University of Jordan, Amman 11942, Jordan; (S.I.); (J.N.); (B.O.); (H.S.); (R.A.)
| | - Hala Sultan
- School of Medicine, The University of Jordan, Amman 11942, Jordan; (S.I.); (J.N.); (B.O.); (H.S.); (R.A.)
| | - Runa Amoudi
- School of Medicine, The University of Jordan, Amman 11942, Jordan; (S.I.); (J.N.); (B.O.); (H.S.); (R.A.)
| | - Justin Z. Amarin
- Office of Scientific Affairs and Research, King Hussein Cancer Center, Amman 11941, Jordan; (J.Z.A.); (S.A.-G.)
| | - Sura Al-Ghnimat
- Office of Scientific Affairs and Research, King Hussein Cancer Center, Amman 11941, Jordan; (J.Z.A.); (S.A.-G.)
| | - Mamoun Ahram
- Department of Physiology and Biochemistry, School of Medicine, The University of Jordan, Amman 11942, Jordan;
| | - Maysa Al-Hussaini
- Department of Pathology and Laboratory Medicine, King Hussein Cancer Center, Amman 11941, Jordan
- Correspondence: ; Tel.: +962-795602694
| |
Collapse
|
2
|
Abemaciclib, A Selective CDK4/6 Inhibitor, Restricts the Growth of Pediatric Ependymomas. Cancers (Basel) 2020; 12:cancers12123597. [PMID: 33271970 PMCID: PMC7760843 DOI: 10.3390/cancers12123597] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2020] [Accepted: 11/29/2020] [Indexed: 12/12/2022] Open
Abstract
Simple Summary Pediatric ependymomas are malignant pediatric brain tumors, and one-third of patients exhibit recurrence within two years of initial treatment. Therefore, this study aimed to find new agents to overcome these chemoresistant tumors and defer radiotherapy treatment. By using integrated bioinformatics and experimental validation, we demonstrated that abemaciclib, a CDK4/6 inhibitor, effectively inhibited cell proliferation and induced cell death. Therefore, treatment with abemaciclib showed encouraging results in preclinical pediatric ependymoma models and provide a new therapeutic strategy in the future. Abstract Pediatric ependymomas are a type of malignant brain tumor that occurs in children. The overall 10-year survival rate has been reported as being 45–75%. Maximal safe surgical resection combined with adjuvant chemoradiation therapy is associated with the highest overall and progression-free survival rates. Despite aggressive treatment, one-third of ependymomas exhibit recurrence within 2 years of initial treatment. Therefore, this study aimed to find new agents to overcome chemoresistance and defer radiotherapy treatment since, in addition, radiation exposure may cause long-term side effects in the developing brains of young children. By using integrated bioinformatics and through experimental validation, we found that at least one of the genes CCND1 and CDK4 is overexpressed in ependymomas. The use of abemaciclib, a highly selective CDK4/6 inhibitor, effectively inhibited cell proliferation and reduced the expression of cell-cycle-related and DNA-repair-related gene expression via the suppression of RB phosphorylation, which was determined through RNA-seq and Western blot analyses. Furthermore, abemaciclib effectively induced cell death in vitro. The efficiency of abemaciclib was validated in vivo using subcutaneously implanted ependymoma tissues from patient-derived xenografts (PDXs) in mouse models. Treatment with abemaciclib showed encouraging results in preclinical pediatric ependymoma models and represents a potential therapeutic strategy for treating challenging tumors in children.
Collapse
|
3
|
Pérez-Ramírez M, García-Méndez A, Siordia-Reyes AG, Chavarría A, Gómez C, García-Hernández N. Pediatric ependymoma: GNAO1, ASAH1, IMMT and IPO7 protein expression and 5-year prognosis correlation. Clin Neurol Neurosurg 2019; 186:105488. [PMID: 31505435 DOI: 10.1016/j.clineuro.2019.105488] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2019] [Revised: 07/18/2019] [Accepted: 08/11/2019] [Indexed: 02/06/2023]
Abstract
OBJECTIVE The aim of this work was to evaluate a pediatric ependymoma protein expression that may be useful as a molecular biomarker candidate for prognosis, correlated with clinical features such as age, gender, histopathological grade, ependymal tumor recurrence and patient survival. PATIENTS AND METHODS Immunohistochemistry assays were performed for GNAO1, ASAH1, IMMT, IPO7, Cyclin D1, P53 and Ki-67 proteins. Kaplan-Meier and Cox analysis were performed for age, gender, histopathological grade, relapse and survival correlation. RESULTS We found that three proteins correlate with histopathological grade and relapse; two proteins correlate with survival; one protein does not correlate with any clinical feature. CONCLUSION Our results suggest that, out of the proteins analyzed, five may be considered suitable prognostic biomarkers and one may be considered a predictive biomarker for response to treatment of pediatric ependymoma.
Collapse
Affiliation(s)
- Monserrat Pérez-Ramírez
- Unidad de Investigación Médica en Genética Humana, Hospital de Pediatría "Dr. Silvestre Frenk Freud", Centro Médico Nacional Siglo XXI, IMSS. Av. Cuauhtémoc 330, Col. Doctores, Del. Cuauhtémoc, 06720, Mexico
| | - Antonio García-Méndez
- Servicio de Neurocirugía Pediátrica, Hospital General "Dr. Gaudencio González Garza", Centro Médico Nacional "La Raza", IMSS, Calzada Vallejo y Jacarandas S/N, Col. La Raza, Del. Azcapotzalco, 02980, Ciudad de México, Mexico
| | - Alicia Georgina Siordia-Reyes
- Servicio de Patología, Hospital de Pediatría "Dr. Silvestre Frenk Freud", Centro Médico Nacional Siglo XXI, IMSS. Av. Cuauhtémoc 330, Col. Doctores, Del. Cuauhtémoc, 06720, Ciudad de México, Mexico
| | - Anahí Chavarría
- Unidad de Investigación en Medicina Experimental, Facultad de Medicina, Universidad Nacional Autónoma de México, 04510, Ciudad de México, Mexico
| | - Celedonio Gómez
- Facultad de Química, Universidad Nacional Autónoma de México, Avenida Ciudad Universitaria 3000, Coyoacán, 04360, Ciudad de México, Mexico
| | - Normand García-Hernández
- Unidad de Investigación Médica en Genética Humana, Hospital de Pediatría "Dr. Silvestre Frenk Freud", Centro Médico Nacional Siglo XXI, IMSS. Av. Cuauhtémoc 330, Col. Doctores, Del. Cuauhtémoc, 06720, Mexico.
| |
Collapse
|
4
|
Wang Q, Li F, Liao Z, Li K, Yang X, Lin Y, Zhao Y, Weng S, Xia Y, Ye Y, Li S, Wang C, Lin Y. Low level of Cyclin-D1 correlates with worse prognosis of clear cell renal cell carcinoma patients. Cancer Med 2019; 8:4100-4109. [PMID: 31183974 PMCID: PMC6675723 DOI: 10.1002/cam4.2313] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2019] [Revised: 05/08/2019] [Accepted: 05/15/2019] [Indexed: 12/19/2022] Open
Abstract
Cyclin-D1 (CCND1) belongs to the highly conserved cyclin family whose members are characterized by abundant expression during the cell cycle. As an oncogene, high level of CCND1 was observed and related to poor prognosis and tumor recurrence in many cancers. In this study, we focused on the role of CCND1 in the clinical outcome of clear cell renal cell carcinoma (ccRCC). Gene Expression Omnibus database, The Cancer Genome Atlas database, and immunohistochemical staining were used. The mRNA and protein levels of CCND1 were significantly enhanced in ccRCC tumor tissues. However, the low level of CCND1, but not high level of CCND1, was related to poor prognosis and tumor recurrence in ccRCC. Further analysis showed that CCND1 mRNA level decreased with increasing ccRCC tumor grades and the rate of recurrence in ccRCC patients. In a nomogram model, the CCND1 mRNA level was shown to help predict ccRCC patient recurrence. CCND1 is a strong determinant for prediction of recurrence. The patients with high CCND1 level appear to have a more favorable prognosis together with more frequent low-grade tumors and low rate of recurrence. This is the first study to investigate the prognostic roles of CCND1 in ccRCC and discovered that CCND1 had an unconventional positive impact on the clinical outcome of ccRCC patients.
Collapse
MESH Headings
- Biomarkers, Tumor/genetics
- Biomarkers, Tumor/metabolism
- Carcinoma, Renal Cell/diagnosis
- Carcinoma, Renal Cell/genetics
- Carcinoma, Renal Cell/metabolism
- Carcinoma, Renal Cell/pathology
- Cyclin D1/genetics
- Cyclin D1/metabolism
- Down-Regulation
- Female
- Gene Expression Regulation, Neoplastic
- Humans
- Kidney Neoplasms/diagnosis
- Kidney Neoplasms/genetics
- Kidney Neoplasms/metabolism
- Kidney Neoplasms/pathology
- Male
- Neoplasm Grading
- Neoplasm Recurrence, Local/diagnosis
- Neoplasm Recurrence, Local/genetics
- Neoplasm Recurrence, Local/metabolism
- Neoplasm Recurrence, Local/pathology
- Nomograms
- Prognosis
Collapse
Affiliation(s)
- Qing‐shui Wang
- Provincial University Key Laboratory of Cellular Stress Response and Metabolic Regulation, Key Laboratory of Opto Electronic Science and Technology for Medicine of Ministry of Education, College of Life SciencesFujian Normal UniversityFuzhouP.R. China
| | - Feng Li
- Department of PathologyProvincial Clinical Medical College of Fujian Medical UniversityFuzhouP.R. China
| | - Zi‐qiang Liao
- Provincial University Key Laboratory of Cellular Stress Response and Metabolic Regulation, Key Laboratory of Opto Electronic Science and Technology for Medicine of Ministry of Education, College of Life SciencesFujian Normal UniversityFuzhouP.R. China
| | - Ke Li
- Provincial University Key Laboratory of Cellular Stress Response and Metabolic Regulation, Key Laboratory of Opto Electronic Science and Technology for Medicine of Ministry of Education, College of Life SciencesFujian Normal UniversityFuzhouP.R. China
| | - Xin‐liu Yang
- Provincial University Key Laboratory of Cellular Stress Response and Metabolic Regulation, Key Laboratory of Opto Electronic Science and Technology for Medicine of Ministry of Education, College of Life SciencesFujian Normal UniversityFuzhouP.R. China
| | - You‐yu Lin
- Provincial University Key Laboratory of Cellular Stress Response and Metabolic Regulation, Key Laboratory of Opto Electronic Science and Technology for Medicine of Ministry of Education, College of Life SciencesFujian Normal UniversityFuzhouP.R. China
| | - Yi‐lin Zhao
- Provincial University Key Laboratory of Cellular Stress Response and Metabolic Regulation, Key Laboratory of Opto Electronic Science and Technology for Medicine of Ministry of Education, College of Life SciencesFujian Normal UniversityFuzhouP.R. China
| | - Shu‐yun Weng
- Provincial University Key Laboratory of Cellular Stress Response and Metabolic Regulation, Key Laboratory of Opto Electronic Science and Technology for Medicine of Ministry of Education, College of Life SciencesFujian Normal UniversityFuzhouP.R. China
| | - Yun Xia
- Provincial University Key Laboratory of Cellular Stress Response and Metabolic Regulation, Key Laboratory of Opto Electronic Science and Technology for Medicine of Ministry of Education, College of Life SciencesFujian Normal UniversityFuzhouP.R. China
| | - Yan Ye
- Provincial University Key Laboratory of Cellular Stress Response and Metabolic Regulation, Key Laboratory of Opto Electronic Science and Technology for Medicine of Ministry of Education, College of Life SciencesFujian Normal UniversityFuzhouP.R. China
| | - Su‐huan Li
- Provincial University Key Laboratory of Cellular Stress Response and Metabolic Regulation, Key Laboratory of Opto Electronic Science and Technology for Medicine of Ministry of Education, College of Life SciencesFujian Normal UniversityFuzhouP.R. China
| | - Chen‐yi Wang
- Provincial University Key Laboratory of Cellular Stress Response and Metabolic Regulation, Key Laboratory of Opto Electronic Science and Technology for Medicine of Ministry of Education, College of Life SciencesFujian Normal UniversityFuzhouP.R. China
| | - Yao Lin
- Provincial University Key Laboratory of Cellular Stress Response and Metabolic Regulation, Key Laboratory of Opto Electronic Science and Technology for Medicine of Ministry of Education, College of Life SciencesFujian Normal UniversityFuzhouP.R. China
| |
Collapse
|
5
|
Association of MicroRNAs with the Clinicopathologic Characteristics of Ependymoma. J Mol Neurosci 2018; 66:307-313. [DOI: 10.1007/s12031-018-1178-z] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2018] [Accepted: 09/17/2018] [Indexed: 10/28/2022]
|
6
|
Liang ML, Hsieh TH, Liu YR, Chen YW, Lee YY, Chang FC, Lin SC, Huang MC, Donald Ming-Tak H, Wong TT, Yen Y, Yang MH. Significance of cyclin D1 overexpression in progression and radio-resistance of pediatric ependymomas. Oncotarget 2017; 9:2527-2542. [PMID: 29416789 PMCID: PMC5788657 DOI: 10.18632/oncotarget.23509] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2017] [Accepted: 12/13/2017] [Indexed: 11/25/2022] Open
Abstract
Due to the limited efficacy of chemotherapy, the applications of adjuvant irradiation play an important role for ependymoma treatment. However, in the young ages, the resistance of residual and recurrent tumor, and long-term intellectual sequelae remain the major obstacles of radiotherapy. Understanding the mechanism of therapeutic failure caused by radio-resistance is, therefore, crucial in ependymoma treatment. Here we retrospectively analyze clinic-pathological factors in 82 cases of ependymoma less than 20 years old and identify radio-resistant genes through gene expression microarray followed by qRT-PCR validation and immunohistochemistry staining. Thirty-one out of 82 (37.8%) patients are under 3-year-old. The 10 years PFS and OS are 38% and 60%. Gross-total resection is the single significant prognostic factor for longer 10 years PFS and OS in the multivariant analysis (p<0.05). According to the microarray analysis, CCND1 is up-regulated in supratentorial and infratentorial ependymomas and is associated with DNA repair. We demonstrated that 24 primary and 16 recurrent ependymomas were up-regulated, and 5 out of 7 paired samples exhibited higher CCND1 expression in recurrent tumors. We also found RAD51, another DNA repair gene, was up-regulated in supratentorial and infratentorial ependymomas. Knocking down CCND1 reduced cell proliferation and repressed several genes associated with S-phase and DNA repair. Homologous recombination activities of DNA repair were significantly decreased in CCND1-deficient cells while the level of γH2AX was increased after irradiation. In summary, these observations suggest a robust role of CCND1 in regulating cell proliferation and radio-resistance in ependymomas, providing a potential therapeutic target for pediatric ependymomas.
Collapse
Affiliation(s)
- Muh-Lii Liang
- Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan.,Institutes of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan
| | - Tsung-Han Hsieh
- Comprehensive Cancer Center of Taipei Medical University, Taipei Medical University, Taipei, Taiwan.,Joint Biobank, Office of Human Research, Taipei Medical University, Taipei, Taiwan
| | - Yun-Ru Liu
- Comprehensive Cancer Center of Taipei Medical University, Taipei Medical University, Taipei, Taiwan.,Joint Biobank, Office of Human Research, Taipei Medical University, Taipei, Taiwan
| | - Yi-Wei Chen
- Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan
| | - Yi-Yen Lee
- Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan
| | - Feng-Chi Chang
- Department of Radiology, Taipei Veterans General Hospital, Taipei, Taiwan
| | - Shih-Chieh Lin
- Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
| | - Ming-Chao Huang
- Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan
| | - Ho Donald Ming-Tak
- Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, Taiwan
| | - Tai-Tong Wong
- Comprehensive Cancer Center of Taipei Medical University, Taipei Medical University, Taipei, Taiwan.,Department of Neurosurgery, Taipei Medical University Hospital, Taipei Medical University, Taipei, Taiwan.,Neuroscience Research Center, Taipei Medical University Hospital, Taipei, Taiwan.,Institutes of Clinical Medicine, Taipei Medical University, Taipei, Taiwan
| | - Yun Yen
- Comprehensive Cancer Center of Taipei Medical University, Taipei Medical University, Taipei, Taiwan.,PhD Program for Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.,Research Center of Cancer Translational Medicine, Taipei Medical University, Taipei, Taiwan
| | - Muh-Hwa Yang
- Institutes of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan.,Cancer Research Center & Genome Research Center, National Yang-Ming University, Taipei, Taiwan.,Immunity and Inflammation Research Center, National Yang-Ming University, Taipei, Taiwan.,Division of Hematology-Oncology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.,Genomic Research Center, Academia Sinica, Taipei, Taiwan
| |
Collapse
|